This test requires a blood draw, so please ensure you can refer to a phlebotomist in the clients area before you order this test.

Cancertrack™ is a minimally invasive, blood-based test that analyses ctDNA, CTCs and/or exosomes in the course of cancer. Recurrences or disease progression can thus be detected as early as possible and therapy can be adjusted.

Cancertrack™ can be used to monitor the disease / recurrence or changes in the tumour characteristics, as often as necessary.

Recommended for

• Every person who has been diagnosed with cancer, as a supplement to conventional biopsy for a more robust molecular diagnosis and baseline measurement of cell-free tumour DNA and CTC values before initiation of therapy.
• Every patient who is under treatment for cancer.
• Every patient who is in remission / a cancer survivor and needs monitoring.

The molecular evolution of the tumour including tumour size and molecular diversity, is a continuous process, which is progressing at enormous speed. There are many strategies and drugs available today that can intercept cancerous growth effectively. Thus, earlier detection of the primary / recurrence / drug resistance is essential for an oncologist to make informed decisions.

Analysed:

• 52 Genes ctDNA 
• 20.000 Genes for Gene expression via mRNA
• Pharmacogenomics

Overview

Cancertrack™ is a minimally invasive, blood-based test that analyses ctDNA, CTCs and/or exosomes in the course of cancer. Recurrences or disease progression can thus be detected as early as possible and therapy can be adjusted.

Cancertrack™ can be used to monitor the disease / recurrence or changes in the tumour characteristics, as often as necessary.

Optimally, the treatment is always one step ahead of the cancer. Cancertrack™ ensures real-time monitoring to detect genetic changes in the tumor at an early stage. Clinically relevant mutations can thereby be monitored, or medication can be aligned with the results. CancertrackTM is a extremely robust and multidimensional test that use multi-coordinate and multidimensional probes to track down DNA / RNA released by cancer cells in the patient’s blood.

Markers

CTC & ctDNA: Indication of cancerous activity in the body

CTC & Exosomes: Indication of molecular dynamics in real-time

CTC & ctDNA: Early relapse detection

ctDNA: Molecular signs of drug resistance - Indication of Loss of Heterozygosity (LOH) + Copy Number Variation (CNV)

Practical

Specimen

Whole blood 

Container

• 2 x DCGL Streck tubes
• 2 x EDTA tubes (purple colour cap) of 10 ml each

Volume

15-20 mL

Patient preparation

Require 5-6 hours fasting prior collection